Related Experiment Video
Updated: Jan 29, 2026
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.8K
Immunoglobulin A Nephropathy: New Treatment Options.
Arun Rajasekaran1,2, Dana V Rizk2, Kirk N Campbell3
1Renal Medicine Associates, Albuquerque, New Mexico, USA.
Annual Review of Medicine
|January 27, 2026
Summary
Immunoglobulin A nephropathy (IgAN) is a leading kidney disease causing kidney failure. Recent advances offer new multi-targeted therapies to reduce nephron loss and halt disease progression.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease globally.
- It is characterized by immune complex deposition, leading to glomerular injury and nephron loss.
- Most patients with IgAN progress to kidney failure over time.
Purpose of the Study:
- To review the latest therapeutic developments for IgAN.
- To highlight advancements in understanding IgAN pathogenesis.
- To discuss multi-targeted approaches for managing IgAN.
Main Methods:
- Review of recent pharmacological agents evaluated and approved for IgAN treatment.
- Analysis of advances in understanding IgAN pathogenesis.
- Discussion of therapeutic strategies targeting immunologic and chronic kidney disease mechanisms.
Main Results:
- Significant advances in understanding IgAN pathogenesis have occurred.
- Numerous pharmacological agents have been recently evaluated and approved.
- Surrogate outcomes like proteinuria reduction are accepted for accelerated drug approval.
Conclusions:
- Multitargeted approaches offer maximal benefit for IgAN patients.
- New therapeutic developments focus on reducing nephron loss and halting disease progression.
- The field has seen a plethora of new pharmacological agents for IgAN treatment.
Related Concept Videos
01:31Immunoglobulin-like Cell Adhesion Molecules
4.4K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
4.4K
01:27Open Angle Glaucoma: Treatment
990
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
990
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:24Parkinson's Disease: Treatment
1.1K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.1K
01:22Alzheimer's Disease: Treatment
914
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
914
01:26Anticholinesterase Agents: Poisoning and Treatment
1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K